A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis (PPP)
Enrollment status: Open
Palmoplantar Pustulosis (PPP) is when the body has abnormal immune reactions that cause a potentially serious inflammatory state resulting in long term white or yellow bumps on the skin filled with noninfectious pus or fluid and surrounded by red skin. It affects mainly the skin of the palms of the hands and the soles of the feet. This study is being done to assess the effects of the experimental study drug (ANB019) in patients with PPP. The study will assess the effect of the study drug on your skin symptoms, plaque psoriasis (if present), the pharmacokinetics (PK) (looking at the amount of drug in your blood to evaluate the way the body processes the drug), systemic manifestations (how the PPP affects your body) and your general wellbeing. The safety and tolerability of ANB019 will be monitored throughout the study. The study drug is a protein drug substance that regulates (controls or maintains) the immune system of the body and may be useful in treating patients with PPP. The study is being carried out by a company called IQVIA RDS Inc. on behalf of AnaptysBio, Inc.
Study coordinator: Aaron Rankin, (734) 936-7519 or email@example.com
Please reference Derm #: 733